Equinix (EQIX) estimates, target raised at Citigroup. Shares of EQIX now seen reaching $150, according to Citigroup. Estimates also increased on favorable revenue growth prospects. Buy rating.
HCA (HCA - Get Report) estimates, target boosted at Goldman. Shares of HCA now seen reaching $27, according to Goldman Sachs. Estimates also upped, as the company is realizing a lower tax rate. Neutral rating.
HCA estimates, target raised at UBS. Shares of HCA now seen reaching $35, according to UBS. Estimates also increased on strong Q4 estimates. Buy rating.
Health Net (HNT) numbers increased at BMO. HNT estimates were raised through 2013, BMO Capital said. Company has good operating momentum. Market Perform rating and new $39 price target.Humana (HUM - Get Report) numbers lowered at Jefferies. Shares of HUM now seen reaching $103, Jefferies said. Estimates also lowered as MCOs have traded poorly following earnings releases this season. Buy rating. Humana estimates, target reduced at Goldman. Shares of HUM now seen reaching $103, according to Goldman Sachs. Estimates also cut, given the company's new guidance. Buy rating. NCR (NCR) estimates, target upped at Goldman. NCR estimates were boosted through 2013, Goldman Sachs said. To match the company's new guidance. Buy rating and new $21 price target. Nielsen Holdings (NLSN) numbers lowered at Citigroup. Shares of NLSN now seen reaching $35, according to Citigroup. Estimates also lowered on tougher FX and D&A expenses. Buy rating. Nuance Communications (NUAN) target raised at Oppenheimer. Shares of NUAN now seen reaching $34, Oppenheimer said. Expect solid first quarter as iPhone 4S bolsters key divisions. Outperform rating. SL Green Realty (SLG) numbers raised at UBS. Shares of SLG now seen reaching $85, according to UBS. Estimates also raised on Q4 results and slightly increased leasing assumptions. Buy rating. Towers Watson (TW) numbers raised at Goldman. shares of TW now seen reaching $68, according to Goldman Sachs. Estimates also increased, as higher organic growth is improving margins. Neutral rating. USG (USG) estimates, target raised at Goldman. Shares of USG now seen reaching $8, according to Goldman Sachs. Estimates also increased, given a better pricing environment. Sell rating. Veeco Instruments (VECO) numbers cut at Goldman. VECO estimates were reduced through 2013, Goldman Sachs said. Company has limited visibility. Neutral rating and new $26 price target. >To submit a news tip, email: firstname.lastname@example.org.
Follow TheStreet on Twitter and become a fan on Facebook.